News & Events
2021 Clinical Plans, 4th Quarter, and 2020 Financial Results
Crinetics will host a webcast and conference call on Tuesday, March 30, 2021 at 4:30 p. m. ET to discuss its 2021 clinical plans and financial results for the fourth quarter and full year 2020.
READ MOREWebcast: 2021 Clinical Plans and Fourth Quarter and Full Year 2020 Financial Results
Crinetics will host a webcast and conference call on Tuesday, March 30, 2021 at 4:30 p. m. ET to discuss its 2021 clinical plans and financial results for the fourth quarter and full year 2020.
READ MORECrinetics Pharmaceuticals Pipeline Progress on Display at ENDO 2021
A late-breaking e-poster and oral presentation provided details of the preclinical findings supporting the company’s development of CRN04894 and CRN04777. In addition, a summary of the previously announced ACROBAT Edge Phase 2 results as well as details of an improved tablet formulation of paltusotine were presented:
READ MOREENDO 2021 Presentations Showcase Three Clinical Programs
Details of the improved tablet formulation of paltusotine advancing into Phase 3 studies. Preclinical evidence supporting the development of its SST5 agonist, CRN04777, for the treatment of congenital hyperinsulinism was selected for a late-breaking e-poster presentation. An oral presentation will also be given on the preclinical studies of CRN04894, the company’s lead adrenocorticotropic hormone (ACTH) antagonist for the treatment of diseases associated with excess ACTH such as congenital adrenal hyperplasia (CAH) and Cushing’s disease.
READ MORELead ACTH Antagonist CRN04894 (Cushing's, CAH) Enters Phase 1 Study
This study will assess the safety and tolerability of single and multiple doses of CRN04894 and will measure the effect of CRN04894 on suppression of cortisol, cortisol precursors, and adrenal androgens following exogenous ACTH stimulation.
READ MORECRN04777 (Congenital Hyperinsulinism) Advances to Phase 1 Study
Phase 1 study of CRN04777, an oral, nonpeptide somatostatin receptor type 5 (SST5) agonist being developed as a treatment for congenital hyperinsulinism (congenital HI). Congenital HI is a rare genetic disease associated with dysregulated insulin production in which excess insulin produces life-threatening hypoglycemia (low blood glucose) beginning at birth.
READ MORECrinetics Update 39th Annual J.P. Morgan Healthcare Conference
Webcast: Crinetics Pharmaceuticals' Founder and CEO, Scott Struthers provides 2020 review and 2021 Plans at 39th Annual JP Morgan Healthcare Conference - January 13, 2021 Corporate Slides View Press Release Jess Fye: Hey, good afternoon, everyone. My name's Jess Fye, I'm one of the senior biotech analysts at JP Morgan, and we're continuing the 2021 healthcare conference today with Crinetics. Things are a little different this year, so instead of going across the hall to the breakout room after the presentation, you can ask questions by using that blue ask a question button on your screen.
READ MORETransforming Endocrine Disease Treatment
Be the first to know about the advances we're making in endocrine-rooted care.
Email Signup
Please click CONTINUE below to learn more about a new treatment option. This website contains information about a prescription medicine.
